ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

ישראל - עברית - Ministry of Health

novartis israel ltd - onasemnogene abeparvovec - תרחיף - onasemnogene abeparvovec 2 x 10^13 vg / 1 ml - onasemnogene abeparvovec

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 10 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 15 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 20 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 30 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 40 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - קפסולות בשחרור נרחב - dexmethylphenidate hydrochloride 5 mg - dexmethylphenidate

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob